Increasing HIV-1 Drug Resistance Between 2010 and 2012 in Adults Participating in Population-Based HIV Surveillance in Rural KwaZulu-Natal, South Africa.
PMID: 27002368
2016
AIDS research and human retroviruses
Result: Of those with NRTI mutations, five (0.7%) had only the M184V mutation, two (0.3%) had the K65R mutation alone, one (0.1%) had the M41L mutation alone, and two (0.3%) had multiple thymidine analogue mutations (one with M184V).
Result: Six (0.9%) participants had both NNRTI and NRTI resistance mutations, K103N+M184V being the most common combination.
Discussion: Alternatively, the person who transmitted the virus may have interrupted treatment before the transmission event, thus reducing the likelihood of transmitting the M184V virus.
Discussion: Although recently infected patients not on ART are expected to have
Lamivudine Monotherapy: Experience of Medium-term Outcomes in HIV-infected Children Unable to Adhere to Triple Therapy.
PMID: 27031256
2016
The Pediatric infectious disease journal
Abstract: By preferentially selecting the M184V mutation, lamivudine monotherapy (LM) is occasionally used while awaiting patient readiness for second- or third-line therapy, but this strategy has not been widely studied.
Prevalence of Drug Resistance Associated Mutations Among the Anti Retroviral Therapy Exposed HIV-1 Infected Individuals in Manipur, Northeast India.
Abstract: Antiretroviral-naive adults initiating antiretroviral therapy in Nairobi, Kenya were tested for HIV-1 drug resistance at codons K103N, Y181C, G190A, M184V, and K65R using an oligonucleotide ligation assay.
Introduction: Fifteen of the participants had mutations only to NNRTI (K103N, Y181C, G190A), and three had mutations to NNRTI plus lamivudine (M184V).
Introduction: OLA examined point mutations at K103N, Y181C, G190A, and M184V across all s
HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults.
PMID: 27076106
2016
The Journal of antimicrobial chemotherapy
Abstract: Drug resistance mutations were present in 87/115 samples (75.7%); the most common were M184V/I (52.2%) and K103N (35%).
Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation.
PMID: 27076656
2016
Journal of clinical microbiology
Abstract: Despite focused selection of patients with T215 revertants or singleton mutations, deep sequencing failed to identify the resistant T215Y/F or M184V or any other resistance mutation, indicating that in most of these cases there is no hidden resistance and that the virus detected at diagnosis by population sequencing is the original infecting variant.
Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY(R) System.
Abstract: In terms of loci, the detection rate of the alleles was greater than 97% for M41L, K65R, M184V and G190A, 91.2% for K101E/Q/P, 91.2% for T215F/Y, 89.9% for K103N/S and 80.5% for L210W.
Introduction: In this study, we established a multiplex assay for detecting the drug resistance mutations at 8 loci (M41L, K65R, K101E/Q/P, K103N/S, M184V, G190A, L210W and T215F/Y), which are as
HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naive and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
Result: For NRTIs, the most common ADR-CRM were M184VI (76.0%) and T215YF (26.8%), whereas the most common SDRM were T215 revertants (2.4%) and M41L (2.0%) (Fig 1A).
Result: The frequency and patterns of mutations differed slightly among individuals under first-line ART schemes; however, in all cases higher percentages of M184VI, K103N and P225H were observed (Fig 3A, 3B and 3C).
Result: The highest percentage of NRTIs mutations in subjects on second-line scheme were M184V and T215FY in only 40.0% and 21.7% of the subjects compared to up to 88.0% and 83.0% respectively observed in subjects on other schemes.
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
Discussion: In our study, 60.8% and 79.2% were TAM and M184V, respectively.
Discussion: We next examined the mutation profile among patients with first-line regimen failure and observed that most of the patients had thymidine analogue mutations (TAMs) with or without M184V and NNRTI RAMs.
Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
PMID: 27124362
2016
Journal of acquired immune deficiency syndromes (1999)
Result: Because many of the commonly used cART regimens include either 3TC or FTC, some isolates from virological failures also contained the M184V/I mutation.
Result: DOR potently inhibited the replication of E40K, K101E, V111A, M184I, M184V, K101E/M184I, K101E/M184V, E138K/M184I, and E138K/M184V (all <3 nM).
Result: The ability of RPV to inhibit these E138K/M184I/V RT
HIV mutation literature information.
PMID: 
2016
AIDS research and human retroviruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT